Prediction model for hepatitis B e antigen seroconversion in chronic hepatitis B with peginterferon-alfa treated based on a response-guided therapy strategy

Table 1 Baseline characteristics of patients stratified by the follow-up endpoint

Characteristics	RS (n = 27)	NRS (n = 48)	P value
Sex			0.057
Male	18 (66.7%)	41 (85.4%)
Female	9 (33.3%)	7 (14.6%)
Age (yr)	32.26 ± 6.96	34.33 ± 7.38	0.237
Initial data
ALT (ULN)	3.01 (0.69-4.88)	2.00 (0.98-6.20)	0.773
HBV DNA (lg IU/mL)	4.57 (2.70-7.62)	7.15 (5.35-7.85)	0.057
HBsAg (lg IU/mL)	3.90 (2.84-4.38)	4.30 (3.68-4.70)	0.022
HBeAg (lg S/CO)	2.36 (0.89-2.93)	2.96 (2.05-3.17)	0.014
Prior antiviral therapy
ETV	13 (48.2%)	28 (58.3%)	0.653
TDF	9 (33.3%)	14 (29.2%)
LAM/ADV/LdT	5 (18.5%)	6 (12.5%)
Pre-treatment duration (yr)	2 (1.0-3.5)	2 (1.0-4.0)	0.399
Baseline
ALT (ULN)	0.90 (0.45-1.88)	0.99 (0.65-1.56)	0.446
HBV DNA (lg IU/mL)	2.70 (2.70-2.70)	2.70 (2.70-2.70)	0.375
HBsAg (lg IU/mL)	3.26 (2.61-3.65)	3.51 (3.05-3.82)	0.089
HBeAg (lg S/CO)	0.43 (0.18-1.70)	1.07 (0.63-1.89)	0.035
WBC (× 109/L)	5.89 ± 1.85	5.60 ± 1.71	0.517
N (× 109/L)	3.34 ± 1.37	3.06 ± 1.21	0.385
RBC (× 109/L)	4.99 ± 0.53	5.00 ± 0. 47	0.901
Hb (× 109/L)	146.75 ± 13.64	150.57 ± 15.72	0.323
PLT (× 109/L)	193.63 ± 56.65	192.19 ± 66.45	0.929
Current therapy
PEG-IFNα monotherapy	7 (25.9%)	6 (12.5%)	0.326
PEG-IFNα + ETV	6 (22.2%)	14 (29.2%)
PEG-IFNα + TDF	14 (51.9%)	28 (58.3%)
PEG-IFNα duration (month)	13 (12-18)	9 (6-12)	< 0.001

Values are presented as number (percentage) or mean ± SD or median (Q1-Q3). RS: Responders; NRS: Non-responders; ALT: Alanine aminotransferase; ULN: Upper limit of normal; HBV: Hepatitis B virus; HBsAg: Hepatitis B surface antigen; HBeAg: Hepatitis B e antigen; ETV: Entecavir; TDF: Tenofovir disoproxil; LAM: Lamivudine; ADV: Adefovir dipivoxil; LdT: Telbivudine; PEG-IFNα: Peginterferon-alfa; WBC: White blood cell; RBC: Red blood cell; N: Nitride; Hb: Hemoglobin; PLT: Platelet count.

Table 2 Selected variables by multivariate analysis at baseline, week 12, and week 24 to construct predictive models for response at 24 wk post-treatment

	Selected predictive variables	Multivariate analysis OR (95%CI)	P value
Baseline	HBsAg ≤ 1000 IU/mL	0.466 (0.153-1.421)	0.180
	HBeAg ≤ 3 S/CO	0.222 (0.074-0.671)	0.008
12 wk	HBsAg ≤ 600 IU/mL	0.271 (0.091-0.810)	0.019
	HBeAg ≤ 3 S/CO	0.230 (0.079-0.668)	0.007
24 wk	HBsAg ≤ 300 IU/mL	0.225 (0.067-0.759)	0.016
	HBeAg ≤ 2 S/CO	0.089 (0.027-0.297)	< 0.001

HBsAg: Hepatitis B surface antigen; HBeAg: Hepatitis B e antigen; OR: Odds ratio; CI: Confidence interval.